Opko   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Miami FL United States (1991)

Organization Overview

First Clinical Trial
2004
NCT00722384
First Marketed Drug
2016
calcifediol
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Associate Director Clinical Affairs OPKO Biologics | EIRGEN | Epigenetix, Inc. | Opko Biologics | OPKO Health | OPKO Health, Inc. | Opko Health Spain, S.L.U. | OPKO IP Holdings II, Inc. | OPKO IRELAND GLOBAL | OPKO Ireland Global Holdings Ltd. | Opko Renal | OPKO Renal | SVP at Opko Health

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Bone Neoplasms (Phase 1)

Coronavirus Infections (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dwarfism, Pituitary (Phase 3)

Edema (Phase 2)

Endocrine System Diseases (Phase 3)

Hemophilia A (Phase 2)

Hemophilia B (Phase 2)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Hypocalcemia (Phase 1)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 2)

Macular Degeneration (Phase 3)

Macular Edema (Phase 2)

Neoplasm Metastasis (Phase 4)

Obesity (Phase 1)

Prostatic Neoplasms (Phase 1)

Psoriasis (Phase 2)

Renal Insufficiency (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Vitamin D Deficiency (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 48
  • # of Trial APIs: 33